Validation of a Spanish version of the Revised Fibromyalgia Impact Questionnaire (FIQR) by Monika Salgueiro et al.
Salgueiro et al. Health and Quality of Life Outcomes 2013, 11:132
http://www.hqlo.com/content/11/1/132RESEARCH Open AccessValidation of a Spanish version of the Revised
Fibromyalgia Impact Questionnaire (FIQR)
Monika Salgueiro1, Juan Miguel García-Leiva2, Javier Ballesteros1,3, Javier Hidalgo2, Rocío Molina2
and Elena P Calandre2*Abstract
Background: The Revised version of the Fibromyalgia Impact Questionnaire (FIQR) was published in 2009. The aim
of this study was to prepare a Spanish version, and to assess its psychometric properties in a sample of patients
with fibromyalgia.
Methods: The FIQR was translated into Spanish and administered, along with the FIQ, the Hospital Anxiety
Depression Scale (HADS), the 36-Item Short-Form Health Survey (SF-36), and the Brief Pain Inventory (BPI), to 113
Spanish fibromyalgia patients. The administration of the Spanish FIQR was repeated a week later.
Results: The Spanish FIQR had high internal consistency (Cronbach’s α was 0.91 and 0.95 at visits 1 and 2
respectively). The test-retest reliability was good for the FIQR total score and its function and symptoms domains
(intraclass correlation coefficient (ICC > 0.70), but modest for the overall impact domain (ICC = 0.51). Statistically
significant correlations (p < 0.05) were also found between the FIQR and the FIQ scores, as well as between the
FIQR scores and the remaining scales’ scores.
Conclusions: The Spanish version of the FIQR has a good internal consistency and our findings support its validity
for assessing fibromyalgia patients. It might be a valid instrument to apply in clinical and investigational grounds.
Keywords: Fibromyalgia, Revised fibromyalgia impact questionnaire, Linguistic validation, Psychometric properties,
Instrumental studyResumen
Antecedentes: El Cuestionario de Impacto de Fibromialgia (FIQ) ha sido utilizado como medida de valoración en
numerosos estudios clínicos. En 2009 se publicó en inglés su versión revisada (FIQR). El presente estudio se llevó a
cabo para traducir al español y validar dicha versión.
Pacientes y Método: La traducción fue realizada por dos de los autores. La versión traducida del FIQR se
administró a 113 pacientes con fibromialgia junto con el FIQ, la Escala Hospitalaria de Ansiedad y Depresión, el
Cuestionario de Salud SF-36 y la versión abreviada del Cuestionario Breve de Dolor. Una semana después se
administró de nuevo el FIQR. Su consistencia interna se evaluó mediante el coeficiente α de Cronbach. Se
calcularon los coeficientes de correlación intraclase (ICC) entre las puntaciones de la nueva versión y la anterior, así
como las subescalas del Cuestionario SF-36, de la Escala Hospitalaria de Ansiedad y Depresión y del Inventario
Breve de Dolor. La fiabilidad test-retest se evaluó igualmente mediante coeficientes de correlación intraclase.
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Resultados: El coeficiente α de Cronbach de la versión en estudio fue elevado (0,91 en la primera visita y de 0,95
en la segunda). La fiabilidad test-retest fue buena para la puntuación total del FIQR y para las dimensiones de
función y síntomas ( ICC ≥ 0,70) pero modesta para la dimensión de impacto global (ICC = 0,51). Asimismo se
encontraron coeficientes de correlación elevados y estadísticamente significativos respecto a las restantes escalas
aplicadas (p < 0,05).
Conclusión: La versión española del FIQR es un instrumento válido para su uso en la evaluación e investigación
clínicas.
Palabras clave: Fibromialgia, Cuestionario de impacto de fibromialgia revisado, Validación lingüística, Propiedades
psicométricas, Estudio instrumentalBackground
Fibromyalgia syndrome (FMS) is a chronic musculoskel-
etal disorder characterized by widespread and diffuse pain,
often accompanied by fatigue, sleep disturbances, and de-
pressed mood [1]. It significantly impairs the quality of life
of the patients and can be highly disabling [2]. Since nei-
ther diagnostic laboratory tests nor specific radiological
findings are available for its diagnosis, the assessment of
pain severity and accompanying symptoms is considered
essential on this regard, as well as its impact on the func-
tional capacity and the quality of life of FMS patients.
Burckhardt et al. [3] developed and published a tool to
measure the impact of FMS symptoms on daily living abil-
ities and general health status, the Fibromyalgia Impact
Questionnaire (FIQ). The authors’ purpose was to take
into account not only the pain, but also symptoms such
as restless sleep, fatigue, muscular stiffness, anxiety, or
depression, and their impact on perceived quality of
life in the previous week.
The FIQ has been translated and validated in 14 differ-
ent languages, and has been used as an outcome measure
in more than 300 research papers. In fact, it is considered
the most sensitive method to evaluate the clinical course
of the FMS as well as its response to treatment in clinical
trials [4-6]. The questionnaire, however, has been criticized,
mainly due to the cumbersome scoring algorithm used, and
the absence of important issues such as cognitive impair-
ment, postural balance, or environmental sensitivity [7].
In response to such criticisms, Bennett and his col-
leagues published, in 2009, a revised version of the ques-
tionnaire, the FIQR [8]. The improved proposed tool
disposes of the Likert items and the visual analogue scales,
and assesses the severity of symptoms in using discrete
values shown in 11 boxes, valued from 0 to 10, with 10 be-
ing ‘worst’. Furthermore, it includes a wider range of symp-
toms associated with FMS, such as tenderness to touch,
memory disorders, postural balance, hyperalgesia, or sensi-
tivity to environmental factors. Some of the questions, ori-
ginally intended for women living in reasonably affluent
income countries in a previous FIQ, were reformulated to
be suitable for both men and women of all socioeconomiclevels. As in the previous version of the FIQ, all questions
relate to the impact of FMS over the course of the past
7 days.
The FIQR has recently been validated and translated into
Turkish [9] and to Arabian Moroccan [10]. The authors of
this study undertook a translation of the FIQR (Appendix
A) that was used in a previous study on the risk of suicide
in FMS patients [11]. The aim of this paper was to test the
reliability (internal and test-retest) and construct validity of
the Spanish version of the FIQR.
Materials and methods
Participants
Subjects were recruited from several associations of FMS
patients of different Spanish provinces. To be included in
the study, patients had to fulfill the American College of
Rheumatology criteria for FMS published in 1990 [1]. The
only exclusion criterion was a medical, psychiatric, or cog-
nitive disorder that impeded the patient’s ability to correctly
answer the Case Report Form (CRF). In order to include a
representative sample of Spanish FMS patient, age and co-
morbidity were not considered as exclusion criteria.
Those patients who volunteered to participate were given
for completion a CRF that included sociodemographic data,
the proposed Spanish version of the Revised Fibromyalgia
Impact Questionnaire (FIQR), the validated Spanish versions
of the original FIQ, the Hospital Anxiety and Depression
Scale (HADS), the Short Form 36 Health Survey (SF-36),
and the Brief Pain Inventory (BPI). All patients completed
these instruments on the day of the visit, and one week later
participants were reappraised by using only the FIQR.
The study protocol was approved by the Human Re-
search Ethics Committee of the University of Granada,
and all the patients signed a consent form attesting their
willingness to participate in the study.
Assessment tools
Fibromyalgia Impact Questionnaire (FIQ)
The FIQ [3] is a 10-item self-report questionnaire devel-
oped to measure both physical and psychological symptoms
of FMS, and their interference in daily living tasks and in
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4-point Likert scales for assessing patients’ ability to carry
out physical activities over the course of the past 7 days.
Items 2 and 3 indicate the number of days in the former
week that the patients felt good, and how many days of
work they missed. Finally, the remaining seven questions
use a 10-centimeter visual analogue scale in order to
measure patients’ disability at work, and severity of pain,
fatigue, morning tiredness, muscular stiffness, anxiety, and
depression. The questionnaire scoring procedure requires
recoding of item 3, and standardizing raw scores for calcu-
lating the arithmetic mean value ranging from 0 (lowest
impact) to 10 (maximum impact). The consensus version
[12] made from the different Spanish FIQ forms was used.
Revised Fibromyalgia Impact Questionnaire (FIQR)
The FIQR [8] is a 21-item self-administered question-
naire. All items are visual analogue scales with 11 boxes
discreetly scoring from 0 to 10. From the direct answers
three linked sets of domains can be calculated: (i) func-
tion, which is the sum of the first 9 items divided by 3,
and can take a value between 0 and 30; (ii) overall im-
pact, which is the sum of the items 10 and 11, and can
take a value between 0 and 20; and (iii) symptoms,
which is calculated by adding the raw score of the items
from 12 to 21 divided by 2, and can take a value between
0 and 50. The total FIQR, whose maximal score is 100,
is the sum of the three domain scores, and represents
the overall impact of symptoms on quality of life.
The Spanish translation of the original questionnaire
was performed and agreed by two bilingual authors of
the study (EPC and JMGL) [See Additional file 1].
Hospital Anxiety and Depression Scale (HADS)
The Hospital Anxiety and Depression Scale (HADS)
[13] is commonly used to determine the levels of anx-
iety and depression that a patient is experiencing. This
scale specifically avoids reliance on aspects of these
conditions that are also common to somatic symptoms
or illness, such as fatigue or insomnia, so that it is very
useful in the assessment of anxiety and depression in
patients with physical illness. It is a 14-item scale, seven
of the items related to anxiety and seven related to de-
pression. Each item is scored from 0 to 3 by using a
Likert scale. Overall rates of either anxiety or depres-
sion can take values comprised between 0 and 21, with
higher scores indicative of greater severity of symptoms.
The validated Spanish version [14] was used.
Short Form (36) Health Survey (SF-36)
The Short Form (36) Health Survey (SF-36) [15] provides
a profile of health status and is often used to assess the
health related quality of life [16]. The questionnaire con-
sists of eight subscales: vitality, physical functioning, bodilypain, general health perception, physical role functioning,
emotional role functioning, social role functioning, and
mental health, which are the weighted sums of the ques-
tions in their section. Each scale is directly transformed into
a 0–100 scale on the assumption that each question carries
equal weight. Therewith, two global domains of health can
be calculated, named Physical Component Summary (PCS)
and Mental Component Summary (MCS). In all subscales
and domains higher scores refer to better health status. The
Spanish version of SF-36 adapted by Alonso and collabora-
tors [17] was used.Brief Pain Inventory (BPI)
The Brief Pain Inventory (BPI) [18] is a validated, widely
used, self-administered instrument developed to assess
pain interference with daily functions [19]. It uses visual
analogue scales ranging from 0 to 100 to measure both
the intensity of the pain (sensory dimension) and its inter-
ference with the patient’s life (reactive dimension). It also
queries the patient about pain relief, pain quality, and
patient perception of the cause of pain. The validated
Spanish version of BPI [20] was used.Statistics
Demographic data were analyzed using the descriptive
statistics of mean, standard deviation (SD) and range.
Age and duration of pain were used as continuous vari-
ables. The remaining variables were used as dichotom-
ous ones and described using the absolute and relative
frequencies.
Test-retest reliability was assessed using the intraclass
correlation coefficients (ICC) between the FIQR scores
of the first and the 1-week follow-up evaluations. We
used a two-way random effect model to estimate the
ICC and 95% confidence intervals (CI) [21]. Internal
consistency was determined using Cronbach’s α coeffi-
cient. Construct validity was evaluated with Pearson’s r
correlation coefficients correlating the FIQR total score
with the former FIQ, the HADS, and the BPI for con-
vergent validity, and with the SF-36 for divergent valid-
ity. Guided by previous research on FIQR validations [9,10]
we expected to find internal consistency values (Cronbach’s
α) ≥ 0.80, test-retest reliability values (ICC) ≥ 0.70, and con-
vergent and divergent validity values showing at least mod-
erate to important correlations between the FIQR and the
target scales (Pearson’s r values in the range of 0.40 to
0.70). Given these values we estimated that sample sizes in
the range of 20 to 60 subjects would be sufficient to esti-
mate correlations between 0.40 and 0.70 assuming a 5% as
significance level and 90% power.
Statistical analyses were conducted with the SPSS
v17.0 (Chicago, IL, USA) and Stata v12 (College Station,
TX, USA)
Table 2 Test-retest reliability of the Revised Fibromyalgia








FIQR total 68.2 ± 17.5 67.4 ± 19.9 0.82
(0.75 to 0.87)
FIQR function 18.9 ± 6.7 19.2 ± 6.8 0.73
(0.63 to 0.80)
Comb hair 4.48 ± 2.9 4.56 ± 3.1 0.72
(0.62 to 0.80)
Walk for 20 minutes 5.70 ± 3.4 5.75 ± 3.5 0.74
(0.64 to 0.81)
Prepare a meal 4.57 ± 3.0 5.22 ± 3.1 0.66
(0.54 to 0.75)
Clean floors 6.90 ± 2.8 7.16 ± 2.7 0.60
(0.47 to 0.71)
Carry a bag of
groceries
8.23 ± 6.4 7.59 ± 2.7 0.19
(0.01 to 0.36)
Climb a flight of stairs 7.16 ± 2.6 7.25 ± 2.8 0.70
(0.60 to 0.79)
Change bed sheets 6.73 ± 2.5 6.66 ± 2.6 0.74
(0.65 to 0.82)




6.36 ± 2.8 6.81 ± 2.6 0.73
(0.63 to 0.81)
FIQR overall impact 11.8 ± 5.6 12.0 ± 5.9 0.51
(0.36 to 0.63)
Can not achieve goals 5.91 ± 2.9 5.98 ± 3.0 0.59
(0.45 to 0.69)
Feel overwhelmed 5.88 ± 3.3 6.05 ± 3.1 0.37
(0.20 to 0.52)
FIQR symptoms 37.5 ± 8.7 36.1 ± 9.6 0.81
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One hundred and fourteen patients completed the ques-
tionnaires: one of these was excluded because of missing
items. Thus, the study sample consisted of 113 patients.
Their sociodemographic characteristics are shown in
Table 1.
Table 2 shows the main descriptive statistics for the
FIQR at the test and retest visits one week apart as well
as the ICC to estimate the temporal stability of the mea-
surements. The studied sample showed a FIQ total score
of 70.15 (SD: 17.82). Histograms of distributions of FIQ
and FIQR total scores are shown in Figure 1. Cronbach’s
α calculation for the Spanish version of FIQR was 0.91
in the first visit, and 0.95 in the second visit.
The response of the Spanish version of FIQR provided
in the second visit showed a satisfactory temporal stability
on the dimensions assessed by the total FIQR (ICC = 0.82,
95% CI = 0.75 to 0.87), the FIQR function (ICC = 0.73,
95% CI = 0.63 to 0.80), and the FIQR symptoms (ICC= 0.81,
95% CI = 0.73 to 0.87). On the contrary the dimension of
FIQR overall impact showed a low temporal stability (ICC =
0.51, 95% CI = 0.36 to 0.63). Three items of the FIQR func-
tion presented an ICC point estimate below 0.70 (“prepare a
meal”, “clean floors”, and “carry a bag of groceries”) and the
item “go shopping for groceries” presented a significant time
effect (p < 0.05 for the mean difference between visits). The
2 items of the FIQR overall impact presented an ICC below
0.70. Four items of the FIQR symptoms presented an ICC
below 0.70 (“pain rating”, “energy rating”, “stiffness rating”,
and “sleep quality”), whereas the test-retest ratings for FIQR
symptoms, stiffness, and memory problems showed a sig-
nificant time effect (p < 0.05).Table 1 Sociodemographics of fibromyalgia syndrome
patients (N = 113)
[N (%)]
Gender
- Female 109 (96.5)
- Male 4 (3.5)
Age in years (mean ± SD) 51.6 ± 9.6
Marital status:
- Unmarried 23 (21.5)
- Married 67 (62.6)
- Divorced 13 (12.2)
- Widowed 3 (2.8)
Education:
- lliterate 9 (8.0)
- Primary 51 (45.5)
- Secondary 37 (33.0)
- Tertiary 14 (12.5)
Disease duration in years (mean ± SD) 8.5 ±7.6
(0.73 to 0.87)
Pain rating 7.73 ± 2.2 7.65 ± 2.2 0.64
(0.52 to 0.74)
Energy rating 7.73 ± 2.3 7.72 ± 2.2 0.63
(0.50 to 0.73)
Stiffness rating 7.39 ± 2.2 6.91 ± 2.6 0.69
(0.57 to 0.78)
Sleep quality 8.62 ± 2.1 8.26 ± 2.1 0.52
(0.38 to 0.64)
Depression level 6.54 ± 3.2 6.47 ± 3.2 0.87
(0.82 to 0.91)
Memory problems 7.53 ± 2.5 7.14 ± 2.5 0.78
(0.69 to 0.84)
Anxiety level 7.18 ± 2.8 6.71 ± 2.9 0.80
(0.72 to 0.86)
Tenderness level 7.43 ± 2.7 7.28 ± 2.9 0.76
(0.68 to 0.83)




8.02 ± 2.2 7.67 ± 2.3 0.71
(0.61 to 0.80)
SD Standard Deviation, ICC intraclass correlation coefficient, 95% CI 95%










































Distribution of basal scores of FIQ
Figure 1 Histograms of FIQ and FIQR showing distribution of basal scores.
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function, overall impact, and symptoms scores, and study
questionnaires were calculated for testing construct valid-
ity according to convergent and divergent validity criteria
(Table 3). The total scores of the FIQR and FIQ were
closely correlated (r = 0.83, p < 0.01). The FIQR total, func-
tion, overall impact, and symptoms scores showed signifi-
cant correlations with HADS depression and anxiety
subscales, pain intensity and its interference with daily ac-
tivities assessed by using BPI (p < 0.01 in every case). Fi-
nally, significant (p < 0.01) inverse correlations were also
found between FIQR total and its domains’ scores, and
quality of life assessed by SF-36 (Table 3).
Discussion
Overall, our findings suggest that the FIQR is a sufficiently
reliable and valid measure of health status in Spanish pa-
tients of FMS.
The sample of patients with FMS in this study presents
the expected demographic and clinical characteristics of the
disorder: middle-aged women, married and with primarystudies, and with several years of duration of the disease
(Table 1). The duration of pain and symptoms of FMS were
highly variable, probably due to the wide age range (30–
87 years) of studied sample.
Participants reported similar scores of FIQR in both
evaluations (68.22, SD: 17.5 and 67.42, SD: 19.89, in the
first and the second visit, respectively). These values are
consistent with those obtained by Srifi and collaborators
[10] (65, SD: 14.5 for the first visit, and 63.2, SD: 16.6 for
the second visit), and are slightly higher than those pub-
lished by Ediz and his colleagues [9] (55.22, SD: 21.96 and
57.16, SD: 22.48, respectively).
The psychometric properties of the Spanish FIQR in
patients with FMS were similar both to those of the ori-
ginal English-language validation study [8] and the two
subsequent Turkish [9] and Arabic Moroccan [10] vali-
dations. Internal consistency of the Spanish FIQR was
found as high as 0.91 for the first visit and 0.95 for the
second visit, indicating acceptable levels of internal
consistency for both assessments. This level of internal
consistency of the Spanish FIQR is close to the one of
Table 3 Revised Fibromyalgia Impact Questionnaire total and dimensions scores construct validity (Pearson’s
correlation coefficients and 95% CI)
FIQR total FIQR function FIQR overall FIQR symptoms
FIQ total 0.83 (0.75 to 0.88) 0.68 (0.56 to 0.77) 0.47 (0.31 to 0.61) 0.83 (0.76 to 0.88)
HADS total 0.69 (0.57 to 0.77) 0.53 (0.38 to 0.66) 0.45 (0.28 to 0.58) 0.70 (0.59 to 0.79)
HADS anxiety 0.66 (0.54 to 0.75) 0.50 (0.35 to 0.63) 0.42 (0.25 to 0.56) 0.68 (0.56 to 0.77)
HADS depression 0.62 (0.49 to 0.72) 0.46 (0.30 to 0.60) 0.39 (0.22 to 0.54) 0.65 (0.53 to 0.75)
BPI severity 0.70 (0.57 to 0.78) 0.51 (0.36 to 0.64) 0.46 (0.31 to 0.61) 0.68 (0.56 to 0.77)
BPI interference 0.84 (0.78 to 0.89) 0.68 (0.57 to 0.77) 0.49 (0.33 to 0.62) 0.85 (0.79 to 0.89)
SF-36:
Physical Component Summary (PCS) −0.53 (−0.65 to −0.38) −0.48 (−0.61 to −0.32) −0.33 (−0.49 to −0.16) −0.48 (−0.61 to −0.32)
Mental Component Summary (MCS) −0.65 (−0.75 to −0.53) −0.47 (−0.60 to −0.31) −0.41 (−0.55 to −0.24) −0.68 (−0.77 to −0.56)
Physical functioning (PF) −0.68 (−0.77 to −0.57) −0.64 (−0.74 to −0.52) −0.35 (−0.50 to −0.17) −0.64 (−0.74 to −0.52)
Physical role functioning (PR) −0.43 (−0.57 to −0.26) −0.32 (−0.47 to −0.14) −0.32 (−0.48 to −0.14) −0.41 (−0.55 to −0.24)
Bodily pain (BP) −0.70 (−0.79 to −0.60) −0.55 (−0.67 to −0.40) −0.45 (−0.59 to −0.29) −0.70 (−0.78 to −0.59)
General health perceptions (GH) −0.63 (−0.73 to −0.50) −0.46 (−0.60 to −0.30) −0.41 (−0.56 to −0.25) −0.64 (−0.74 to −0.51)
Vitality (VT) −0.71 (−0.79 to −0.60) −0.55 (−0.67 to −0.41) −0.45 (−0.59 to −0.29) −0.70 (−0.78 to −0.59)
Social role functioning (SF) −0.65 (−0.74 to −0.52) −0.50 (−0.63 to −0.35) −0.44 (−0.57 to −0.27) −0.63 (−0.73 to −0.50)
Emotional role functioning (RE) −0.54 (−0.66 to −0.40) −0.40 (−0.55 to −0.24) −0.33 (−0.49 to −0.16) −0.56 (−0.68 to −0.42)
Mental health (MH) −0.69 (−0.78 to −0.58) −0.51 (−0.64 to −0.36) −0.41 (−0.56 to −0.25) −0.72 (−0.80 to −0.61)
95% CI 95% confidence interval, FIQR Fibromyalgia Impact Questionnaire Revised, FIQ Fibromyalgia Impact Questionnaire, HADS Hospital Anxiety and Depression
Scale, BPI Brief Pain Inventory, SF-36 Short Form Health Survey.
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0.95, and similar than those published by both Turkish
(α = 0.89 in the first visit, and α = 0.91 in the second
visit) [9], and Moroccan teams (α = 0.91 in the first visit,
and α = 0.94 in the second visit) [10].
The test-retest reliability of the FIQR total score evaluated
with the ICC was 0.82 (Table 2), close to those obtained in
the Turkish (r = 0.84) [9] and Moroccan (r = 0.84) [10] ver-
sions. No test-retest reliability of the original FIQR was
performed by Bennett et al. [8].
Considering separately the three FIQR domains, symp-
toms showed adequate test-retest reliability (ICC = 0.81),
as well as function (ICC = 0.73). However, overall impact
performed somewhat lower (ICC = 0.51, 95% CI = 0.36
to 0.63), and thus point to the possibility of improve-
ment in that domain measure. This could be due to the
high variability showed by FMS patients in terms
achievement goals and overwhelmed feeling and their
impact in daily activities. Although the general reprodu-
cibility of the Spanish FIQR was good, the test-retest re-
liability of some individual items, with ICC values that
varied between 0.19 and 0.87, was lower than those
obtained by the other validated versions of FIQR, those
had Spearman’s rho > 0.70 [9,10]. Of course this is not
unexpected since neither Pearson’s r nor Spearman’s rho
as association measures do take systematic errors for in-
dividual measurements over time into account, and thus
could lead to overestimate the temporal reliability of a
measurement [22]. Future uses of the Spanish FIQR,should consider the reformulation of some of the items
that obtained lower reliability indexes and significant time
effect over the one-week period for test-retest reliability.
Construct validity, both convergent and divergent, of
Spanish translation of FIQR was evidenced by the significant
correlations found between the FIQR total and domains
scores with all the questionnaires used in the validation
process (Table 3). As expected, and as observed in previous
studies [8-10], both the total FIQR and its domains showed
a good correlation with the FIQ, the HADS, the BPI and the
SF-36 scores. A noticeable correlation between FIQR and
previous FIQ (r= 0.83, p < 0.01) and the similar distribution
of their scores (Figure 1), makes it possible to compare the
results of studies using the older version with studies using
the revised version [8].
According to Bennet et al. [8], the FIQR has sound psy-
chometric properties, discriminates between FMS pa-
tients, and patients with rheumatoid arthritis, systemic
lupus erythematosus, or major depression disorder. More-
over, FIQR provides advantages over the previous version.
The use of a numeric rating scale using 11 boxes, scored 0
to 10 in the FIQR as opposed to the combination of Likert
and visual analogue scaling in the FIQ, considerably sim-
plifies the scoring algorithm for the FIQR and obviates the
need to use a ruler to measure visual analogue scales
scores. This simplification and greater efficiency should
make the FIQR easier to use by researchers and physi-
cians. In our experience, the FIQR is substantially easier to
use than the FIQ. The scoring system is much easier to
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tors but also in clinical grounds. Also, the substitution of
the question “How have you felt when you get up in the
morning?” by “Please rate the quality of your sleep” clari-
fies this question for the patients. In relation to the new
added items, patients rated these symptoms in a similar
range than the older ones; this means that they are present
in most patients with fibromyalgia and, therefore, that they
needed to be recorded, making this extension a welcome
addition.
One of the limitations of our study is the fact that pa-
tients were recruited from fibromyalgia patients’ associa-
tions; this probably excluded less affected patients that
frequently are not part of these associations. Also, our
study did not assess some psychometric properties of the
questionnaire, such as the sensitivity to change over time
both with and without treatment. Finally, although pa-
tients were recruited in different parts of Spain in order
ensure both a geographic and cultural diversity, it was not
representative of every Spanish region.
Conclusions
Despite the above mentioned limitations, we think that the
Spanish FIQR can be currently considered a valid, usable
and reliable tool for the assessment of Spanish-speaking
FMS patients. It does not require prior specific training,
and can be used both clinical and in research to be carried
out on FMS patients.
Additional file
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